Overview

Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy

Status:
Active, not recruiting

Trial end date:
2024-05-01

Target enrollment:

Participant gender:

Summary

Multicenter randomized controlled phase III study of nivolumab alone or in combination with ipilimumab as immunotherapy vs standard follow-up in surgical resectable HNSCC after adjuvant therapy

Phase:

Phase 3

Details

Lead Sponsor:

Universitätsklinikum Hamburg-Eppendorf

Collaborators:

Charite University, Berlin, Germany
University Hospital, Essen
Westpfalz-Clinical Center GmbH

Treatments:

Antibodies, Monoclonal
Cisplatin
Ipilimumab
Nivolumab